Carlsmed Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
22.2%projected annual EPS growth
Analyst Coverage
5analysts covering
FY Revenue (est.)
$74.8Mnext fiscal year
FY EPS (est.)
-$1.47next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly16.1MTarget: Full year 2026 revenue guidance of $72 million to $77 million
Gross Margin Quarterly77.1%Target: Maintain mid-70s percentage range
Surgeon User Base Growth Annually19,900.0%Target: Continued expansion of active surgeon base
Watch Items
- U.S. Commercial Launch of aprevo Cervical ACDF Interbody SystemTrigger: Commercial launch execution in 2026Action: Monitor sales adoption, hospital formulary approvals, and surgeon training metrics.
- CMS New Technology Add-On Payment (NTAP) ReimbursementTrigger: Effective starting October 1, 2025, through FY 2026Action: Track hospital utilization rates and billing success for cervical fusion procedures using aprevo.
- Cash Burn and Path to ProfitabilityTrigger: Quarterly cash used in operating activities exceeding $13.0 millionAction: Evaluate operating expense leverage, particularly in R&D and Sales & Marketing, relative to revenue growth.
Research as of 20 Jun 2026